Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Rachel Freedman MD, MPH

Rachel A. Freedman MD, MPH

Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA

Dr. Freedman is an Associate Professor of Medicine at the Harvard Medical School; a Medical Oncologist associated with the Breast Oncology Program at the Dana-Farber Cancer Institute in Boston, MA.

Disclosures

Co-author of this manuscript, Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial, my husband is a shareholder in Firefly, a virtual primary care company; and I have led a trial that received institutional funding from Puma Biotechnology. None of these corporate disclosures are relevant to this work.

Recent Contributions to PracticeUpdate:

  1. Low-Intensity Adjuvant Chemotherapy for Early Breast Cancer in Older Women
  2. Addition of Chemotherapy to Local Therapy in Women Aged 70 Years or Older With Triple-Negative Breast Cancer
  3. Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer

Most Read This Week

Recently Updated